Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Brighten Optix Corporation (6747:TWSE), powered by AI.
Brighten Optix Corporation is currently trading at $199.00. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Brighten Optix Corporation on Alpha Lenz.
Brighten Optix Corporation's P/E ratio is 36.1.
“Brighten Optix Corporation trades at a P/E of 36.1 (premium valuation) with solid ROE of 11.2%.”
Ask for details →Brighten Optix Corporation is a medical device company specializing in the research, development, manufacture, and sale of contact lenses, with a significant presence in both Taiwan and international markets. Its comprehensive product portfolio includes innovative orthokeratology lenses, which non-invasively reshape the cornea for vision correction, rigid gas-permeable lenses addressing needs such as multifocal vision and irregular corneas, and a variety of soft contact lenses under several proprietary brands. The company also offers spectacle lenses, particularly for pediatric myopia management, as well as lens care solutions and rewetting drops. With roots dating back to 1965, Brighten Optix has played a pioneering role in Taiwan’s eye care industry, continually investing in high oxygen permeability and advanced lens designs. Positioned within the healthcare sector and classified under medical specialties, the firm serves a diverse clientele across consumer, clinical, and wholesale channels, helping to shape visual performance solutions in Asia and beyond.
“Brighten Optix Corporation trades at a P/E of 36.1 (premium valuation) with solid ROE of 11.2%.”
Ask for details →Brighten Optix Corporation (ticker: 6747) is a company listed on TWSE in the Healthcare sector (Medical Devices). Market cap is $5.4B.
The current price is 199 with a P/E ratio of 36.14x and P/B of 3.84x.
ROE is 11.16% and operating margin is 18.22%. Annual revenue is $767M.